Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$1.94B+31.41%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shao-Ning Chou
- Sector
- Industrials
- Industry
- Trucking
- Employees
- 3,572
- Beta
- 0.86
- Country
- CN
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -4.05
Financials
Revenue
$1.94B+31.4%Net Income
$-160.93MEBITDA
$-155.98MFree Cash Flow
$-138.52MEPS (diluted)
$-173.80Shares Outstanding (diluted)
925.5K-2.0%Operating Expenses
$249.65MCash & Debt
$294.67MReturn of Capital
$0.00Revenue by Segment (annual)
$2.88BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2023 | $8.32B | $-814.40M | $-870.00 |
| 2022 | $7.74B | $-1.46B | $-1498.40 |
| 2021 | $11.43B | $-1.26B | $-1301.00 |
| 2020 | $30.00B | $-1.68B | $-1744.20 |
| 2019 | $35.18B | $-218.71M | $-225.20 |
| 2018 | $27.96B | $-507.99M | $-528.60 |
| 2017 | $19.99B | $-1.23B | $-1311.40 |
| 2016 | $8.84B | $-1.36B | $-1444.40 |
| 2015 | $5.26B | $-1.06B | $-1122.40 |
| 2014 | $3.07B | $-718.46M | $-761.00 |
Valuation
BESThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·2d ago·Positive
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company's Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses link retinal structure to visual function, enabling focus on regions most likely to respond to treatment OPGx-LCA5 demonstrated sustained improvements in visual…
View source ↗ - Newsprnewswire.com·18d ago·Positive
CARNIVAL CORPORATION OUTPERFORMS GUIDANCE, DELIVERING BEST EVER REVENUES, NET YIELDS AND NET INCOME Record bookings provide a strong foundation for 2027 MIAMI, Sept. 29, 2026 /PRNewswire/ -- Carnival Corporation (NYSE: CCL) announced financial results for the third quarter 2026 and provided an updated outlook.
View source ↗ - Newsprnewswire.com·33d ago·Positive
TRAVEL + LEISURE BRINGS WORLD'S BEST SUMMIT TO LONDON FOR FIRST INTERNATIONAL EDITION LONDON'S GLOBAL INFLUENCE ON TRAVEL AND HOSPITALITY TAKES CENTER STAGE AT TWO-DAY SUMMIT NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Travel + Leisure, a People Inc. brand, will bring its World's Best Summit to London for the first time on October 27 and 28, 2026.
View source ↗ - Newsseekingalpha.com·37d ago·Positive
…pus Genetics: A Resounding Study Success Merits A Higher Valuation Opus Genetics receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases. OPGx-BEST1 showed clinically meaningful visual improvements and strong safety in all Cohort 1 patients, with greater gains in less advanced disease. IRD's pipeline targets large, underserved markets with no approved therapies; cash runway extends into 2029, supporting ongoing pivotal studies.
View source ↗ - Newsseekingalpha.com·37d ago·Positive
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
View source ↗ - Newsglobenewswire.com·38d ago·Positive
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual function, with structural improvements observed in four participants FDA aligned on ≥3 decibels microperimetry i…
View source ↗ - Newsbusinesswire.com·43d ago·Neutral
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion HANAU, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration to support the rapidly growing demand for superconducting materials and technologies required by next-gener…
View source ↗ - Newsglobenewswire.com·45d ago·Positive
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings RESEARCH TRIANGLE PARK, N.C.
View source ↗
Earnings
Typical surprise -31.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Mar 27$-1.00 vs $-0.76miss
Estimates and results for BEST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BEST officers and directors.
No open-market trades in the recent filings. All 3 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
3 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BEST.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.